




## Urinary Incontinence


- Any involuntary loss of urine
- Demonstrated objectively
- *Social or hygienic problem*
- *US - \$10 billion annually*
- **Stress incontinence**
  - Prevalence 8-33%
  - Treatment success variable definition (validated questionnaire, pad test, urodynamic, “improvement”)



Cameron et al  
Open Access Journal of Urology 2011:3  
109-120



## Pathophysiology of SUI



## Pelvic floor muscle training

- Reduces SUI but infrequently cures
- Biofeedback has no additional benefit
- Non-invasive and low risk
- Refer therapist for PFMT



Berghmans et al Br J Urol. 1998; 82: 181-191

## Weight loss

- 1 RCT: patients with BMI > 36
- 8% reduction in BW vs control (1% reduction)
  - More patients with weight loss showed significant reduction (>70% reduction) in incontinence episodes at 6 months
  - Difficult to maintain weight loss




Subak et al NEJM 2009; 360: 481-490

## Duloxetine

- Balanced serotonin and norepinephrine reuptake inhibitor
  - Stimulate pudendal motor neurons and increase striated sphincter contractility
- 1 RCT showed significant reduction in UI episodes (50% vs 27%)
  - Nausea is the commonest side effect
- Europe – approved for SUI
- US FDA – NOT approved

Dmochowski et al J Urol 2003; 170: 1259-1263

## Urethral bulking agent



## Urethral bulking agent

- “Minimal invasive” treatment *for Intrinsic Sphincter Deficiency*
- *Lower success rate c/w open surgery*
- Risks of allergy (collagen), migration (Teflon), erosion, retreatment
- *Collagen, almost historical* (approved in 1993)
  - Allergic 4% (skin test)
  - Reabsorption and retreatment


Cameron et al  
Open Access Journal of Urology 2011;3  
109-120

- *Macroplastique and Coaptite (synthetic)*

- Durable
  - No migration
  - Macroplastique for ISD
    - RCT of Macroplastique vs Collagen
      - Improvement/ Cure at 12 months: 61.5%/ 36.9% (Macroplastique) vs 48%/ 24.8% (Collagen)
- Keegan et al Cochrane Database Syst Rev. 2007; 3: CD003881
- *RCT of Pubovaginal sling vs Macroplastique*
    - *Objective cure at 6 months: 81% after sling vs 9% after Macroplastique*

Maher et al BJOG 2005; 112: 797-801

## Anterior Repair (Colporrhaphy)




## Anterior repair

- Vaginal approach to tackle urethral hypermobility and cystocele
  - Kelly’s plication + cystocele repair
- 2x failure rate (29-38%) compared to retropubic suspension procedures (14-21%) at up to 5 years
- *NOT recommended as primary treatment of SUI*

Glazener et al Cochrane Database Syst Rev. 2001; 1: CD001755

## Bladder neck needle suspension




J Urol Vol.168, 2059–2062, November 2002

## Bladder neck needle suspension

- Suture on needle passer passed from vagina to anterior abdominal wall
- Try to correct urethral hypermobility
- **Failure rate high** (29%) compared to retropubic suspension (16%) at 1 year

Glazener et al Cochrane Database Syst Rev. 2004; 2: CD003636

## Open retropubic suspension



## Open retropubic suspension

- Burch (anterior vaginal wall to ileo-pectineal ligament)
- MMK (bladder neck to pubic symphysis)
  - 1 year: 85-90% success
  - 5 year: 70% dry
- Burch has fewer surgical failure
- **Effective to treat urethral hypermobility (“Gold standard”)**

Lapitan et al Cochrane Database Syst Rev. 2009; 2: CD002912


## Laparoscopic Burch Colposuspension

- Lap vs Open Burch Colposuspension
  - Slightly worse cure rates in laparoscopic group
  - Fewer complications and shorter hospital stay in laparoscopic group

Dean et al Cochrane Database Syst Rev. 2009; 2: CD002912


## Mid-urethral Synthetic Slings

- 1990s Petros and Ulmsten et al
  - Integral theory
  - “Physiologic backboard” is created by fixation of the mid-urethra to pubic bone
  - Mid-urethral support



Petros and Ulmsten Acta Obstet Gynecol Scand. 1997; 166:3-8

## Mid-urethral support



## Retropubic TVT vs SPARC



- TVT Gynecare – bottom-up approach
- SPARC (AMS) – top-down approach
  - Cochrane review 3 RCTs
  - At 12 months follow-up
    - **TVT has higher subjective cure rates (85% vs 77%)**
    - **TVT has higher objective cure rates (92% vs 87%)**



Ogah et al Cochrane Database Syst Rev. 2009; 4: CD006375

## Transobturator TOT vs TVT-O



- **Minimize complications related to vascular and enteric structures c/w retropubic approach**



- TOT – outside-in
- TVT-O – inside-out
  - Similar subjective and objective cure rates
  - **TVT-O has less bladder injuries and voiding dysfunction**

Latthe et al BJOG 2007; 114:522-531

## Retropubic vs Transobturator approach

...‘May take RCT of 30,000 women to show the difference’

Sung et al Am J Obstet Gynecol. 2009; 21:342-347

## Retropubic vs Transobturator

- 2010 multi-center trial with 12-month follow-up
  - Equivalent objective success
  - **Transobturator approach has more leg weakness/ groin numbness**
  - **Retropubic approach has more bladder injuries and de novo voiding dysfunction**

Richter et al NEJM 2010; 362:2066-2076

## Retropubic vs Transobturator

- Small trial (208 patients) with varying degrees of SUI
- Mild SUI: TVT-O and TVT have same outcomes
- **Severe SUI: all were cured by TVT but only 66% were cured with TVT-O**

Araco et al Int Urogynecol J. 2008; 19:917-926

## Mini-slings

- Single vaginal incision
- Self-fixating tips to obturator muscles
- TVT vs Mini-sling
  - Mini-sling has a much higher rate of persistent stress incontinence at 6 weeks and 6 months



Kennelly et al J Urol. 2010; 184: 604-609

## Burch vs TVT

- **Small trials only**
  - Similar success
- **TVT**
  - Shorter operative time/ hospital stay/ costs
  - More bladder/ vaginal perforation

Ward et al BMJ 2002; 13(325): 67  
Novara et al Eur Urol. 2010; 58: 218-238

- **Burch**
  - 8x more likely to develop **pelvic organ prolapse**
  - only in conjunction with other pelvic procedure e.g. abdominal sacrocolpopexy

Brubaker et al NEJM 2006; 354: 1557-1566



## Lap Burch vs TVT

- Similar subjective cure rates
- Better objective cure rates for slings
- **Much simpler for mid-urethral sling**

Dean et al Cochrane Database Syst Rev. 2009; 2: CD002912


## Mid-urethral Slings for ISD

- Abdominal leak point pressure < 60cm water
- TVT vs TOT at 6 months follow-up
  - 21% in TVT group has persistent incontinence
  - 45% in TOT group has persistent incontinence
- TVT is a better option for patients with ISD



Schierlitz et al Obstet Gynecol. 2008; 112: 1253-1261

## Pubovaginal Sling PVS



## Pubovaginal Sling PVS

- **Designed to treat Intrinsic Sphincter Deficiency**
- For Urethral Hypermobility: Burch vs PVS
  - Higher success for PVS
  - **More voiding dysfunction/ obstruction/ urge incontinence**
- For Urethral Hypermobility: PVS vs TVT
  - Similar success
  - Higher bladder injury rates after TVT
  - Higher rates of voiding dysfunction after PVS: needs longer hospitalization and **higher self-catheterization rate**

Albo et al NEJM 2007; 24 (356): 2143-2155

Rehman et al Cochrane Database Syst Rev. 2011; 1: CD001754

*Synthetic mid-urethral slings are minimally invasive, safe and effective for female SUI with high leak point pressure (Urethral Hypermobility)*

Different complication profiles


Cameron et al  
Open Access Journal of Urology 2011:3  
109-120

For Intrinsic Sphincter Deficiency, trial of pubovaginal sling vs mid-urethral sling is needed


Cameron et al  
Open Access Journal of Urology 2011:3  
109-120

### Male SUI

- Mainly iatrogenic
- Post-Radical Prostatectomy: 2-43%
  - Frequently quoted figures at 12 months
    - 0 pad: 90%
    - 0-1 pad: 10%
    - > 1 pad: 1%
- Radiotherapy: 1-16%
- TURP 1-3%



Trost et al Adv Urol. 2012: 287489




### Male SUI

- No universally accepted evaluative methods
  - Subjective pad usage
  - 24-hour pad tests
  - “eye-balling”



### Besides surgery

- Penile clamps
- Urethral bulking agents
- Catheters



## Before surgery

- Significant history
  - Urothelial carcinoma, urolithiasis, urethral stricture, bladder neck contracture
- Exclude infection and retention
- Normal bladder capacity and compliance
- **No other urethral/ bladder pathologies**
- **Hand and mental capacity**
- **At least 6-12 months after initial events**

Trost et al Adv Urol. 2012: 287489

## Male Slings

- Bone-Anchored Sling
  - Direct compression of bulbar urethra
- Retrourethral Transobturator Sling
  - Angulation of bulbar urethra
- Adjustable Retropubic Sling
- Quadratic Sling



Trost et al Adv Urol. 2012: 287489

## Bone Anchored Slings

- Cure 37-67%
- Improvement 10-40%
- **Prognostic factors**
  - **Pre-op severity of incontinence**
  - **? Prior radiation therapy**
- Complications
  - Infection 2-15%, erosion 0-3%, removal 0-13%
  - De novo urgency 0-14%, **pain 0-73% (resolves in 4 months)**



Trost et al Adv Urol. 2012: 287489

## Retrourethral Transobturator Slings

- Cure 52-74%
- Improvement 16-27%
- Complications
  - **Temporary retention of urine** < 2 weeks: 0-24%
  - Urethral injury: 0-3%
  - Pain: 0-34%
  - Sling removal: 0-4%



Trost et al Adv Urol. 2012: 287489

## Retrourethral Transobturator Slings


- Salvage after failed AUS
  - Cure 79%
  - Improvement 21%
- Salvage after failed slings
  - Cure 35%
  - Improvement 55%

Christine et al Urology 2010; 76(6): 1321-1324

Soljanik et al European Urology 2010; 58(5): 767-772

## Adjustable Retropubic Sling


- Success 54-79%
- **Need adjustment 10-100%**
- **More complications**
  - Infection 5-7%, erosion 3-13%, removal 2-35%, **bladder perforation** 5-29%, **retention** 35%, pain 4-38%



Trost et al Adv Urol. 2012: 287489

## Artificial Urinary Sphincter

- Popularized since 1978
- Most popular model AMS 800
  - Pump
  - Cuff of size 3.5 – 14cm
  - Reservoir in different pre-set pressures
  - Deactivation button



## AUS outcomes

- Much longer mean follow-up 3 to 7.7 years
- Continent (0-1 pads)
  - 59-91%
- Complications
  - Urethral atrophy 4-10%, erosion 4-10%, infection 1-14%, mechanical failure 0-29%
- Most revisions are within first 36-48 months
- **Long-term mechanical failure rate: 36% at 10 years**

Trost et al Adv Urol. 2012: 287489

## Sling or AUS

- No universally accepted standard of stratification
  - Degree of incontinence
  - Inability to function AUS
  - Prior sling or AUS
  - Patient or Surgeon preference/ expertise
  - Literature
  - Complications

AMS 800 Artificial Urinary Sphincter is the gold standard of treatment of male SUI

*... since late 1990s, male sling was introduced as a surgical alternative for patients with low volume incontinence (1-3 pads/ day)*

Trost et al Adv Urol. 2012: 287489

## New AUS

- ZSI 375 device (Zephyr Surgical Implants, Geneva, Switzerland)
  - One-size-fit-all adjustable cuff
  - Pump and pressure-regulating tank together (pressure adjustable after insertion)
  - NO abdominal reservoir



Staerman et al BJUI 2013  
Apr;111(4 Pt B):E202-6

## ZSI 375 AUS

- Median follow-up 15.4 months
  - Social continence (0-1 pads/ day) 78% at 3 months, 73% at 6 months
  - Removal in 4 out of 36 patients (erosion/ infection)

Staerman et al BJUI 2013  
Apr;111(4 Pt B):E202-6



*...Uncommon to have complete resolution of incontinence*

... patient counselling on reasonable expectations and potential complications

